Literature DB >> 33436863

Prognostic significance of CD8+ T-cells density in stage III colorectal cancer depends on SDF-1 expression.

Alexandros Lalos1, Ali Tülek2, Nadia Tosti3, Robert Mechera2, Alexander Wilhelm2, Savas Soysal2, Silvio Daester2,4, Venkatesh Kancherla3, Benjamin Weixler5, Giulio C Spagnoli6, Serenella Eppenberger-Castori3, Luigi Terracciano3, Salvatore Piscuoglio3,7, Markus von Flüe2,7, Alberto Posabella2, Raoul A Droeser8.   

Abstract

Since colorectal cancer (CRC) remains one of the most common malignancies, a tremendous amount of studies keep taking place in this field. Over the past 25 years, a notable part of the scientific community has focused on the association between the immune system and colorectal cancer. A variety of studies have shown that high densities of infiltrating CD8+ T-cells are associated with improved disease-free and overall survival in CRC. Stromal cell-derived factor-1 (SDF-1) is a protein that regulates leukocyte trafficking and is variably expressed in several healthy and malignant tissues. There is strong evidence that SDF-1 has a negative prognostic impact on a variety of solid tumors. However, the existing data do not provide sufficient evidence that the expression of SDF-1 has an influence on CRC. Knowing nowadays, that the microenvironment plays a crucial role in the development of cancer, we hypothesized that the expression of SDF-1 in CRC could influence the prognostic significance of CD8+ T-cells, as an indicator of the essential role of the immune microenvironment in cancer development. Therefore, we explored the combined prognostic significance of CD8+ T-cell density and SDF-1 expression in a large CRC collective. We analyzed a tissue microarray of 613 patient specimens of primary CRCs by immunohistochemistry (IHC) for the CD8 + T-cells density and the expression of SDF-1 by tumor cells and tumor-infiltrating immune cells. Besides, we analyzed the expression of SDF-1 at the RNA level in The Cancer Genome Atlas cohort. We found that the combined high CD8+ T-cell infiltration and expression of SDF-1 shows a favorable 5-year overall survival rate (66%; 95% CI 48-79%) compared to tumors showing a high expression of CD8+ T-cell only (55%; 95% CI 45-64%; p = 0.0004). After stratifying the patients in nodal negative and positive groups, we found that the prognostic significance of CD8+ T-cell density in nodal positive colorectal cancer depends on SDF-1 expression. Univariate and multivariate Hazard Cox regression survival analysis considering the combination of both markers revealed that the combined high expression of SDF-1 and CD8+ T-cell density was an independent, favorable, prognostic marker for overall survival (HR = 0.34, 95% CI 0.17-0.66; p = 0.002 and HR = 0.45, 95% CI 0.23-0.89; p = 0.021, respectively). In our cohort there was a very weak correlation between SDF-1 and CD8+ T-cells (rs = 0.13, p = 0.002) and in the trascriptomic expression of these two immune markers display a weak correlation (rs = 0.28, p < 0.001) which was significantly more pronounced in stage III cancers (rs = 0.40, p < 0.001). The combination of high CD8+ T-cell density and expression of SDF-1 represents an independent, favorable, prognostic condition in CRC, mostly in patients with stage III disease.

Entities:  

Year:  2021        PMID: 33436863      PMCID: PMC7803998          DOI: 10.1038/s41598-020-80382-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  41 in total

1.  CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer.

Authors:  Nozomu Sakai; Hiroyuki Yoshidome; Takashi Shida; Fumio Kimura; Hiroaki Shimizu; Masayuki Ohtsuka; Dan Takeuchi; Masahiro Sakakibara; Masaru Miyazaki
Journal:  Clin Exp Metastasis       Date:  2011-11-11       Impact factor: 5.150

2.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.

Authors:  O Nakano; M Sato; Y Naito; K Suzuki; S Orikasa; M Aizawa; Y Suzuki; I Shintaku; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

4.  Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

Authors:  Qian Shi; James Paul; Axel Grothey
Journal:  N Engl J Med       Date:  2018-07-26       Impact factor: 91.245

5.  Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis.

Authors:  Sameh Amara; Ines Chaar; Meriem Khiari; Donia Ounissi; Marwa Weslati; Rahma Boughriba; Abdelmajid B Hmida; Saadia Bouraoui
Journal:  Cancer Biomark       Date:  2015       Impact factor: 4.388

Review 6.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

7.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Authors:  Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Anne Berger; Gabriela Bindea; Tchao Meatchi; Patrick Bruneval; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès; Jérôme Galon
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

8.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Authors:  Franck Pagès; Bernhard Mlecnik; Florence Marliot; Gabriela Bindea; Fang-Shu Ou; Carlo Bifulco; Alessandro Lugli; Inti Zlobec; Tilman T Rau; Martin D Berger; Iris D Nagtegaal; Elisa Vink-Börger; Arndt Hartmann; Carol Geppert; Julie Kolwelter; Susanne Merkel; Robert Grützmann; Marc Van den Eynde; Anne Jouret-Mourin; Alex Kartheuser; Daniel Léonard; Christophe Remue; Julia Y Wang; Prashant Bavi; Michael H A Roehrl; Pamela S Ohashi; Linh T Nguyen; SeongJun Han; Heather L MacGregor; Sara Hafezi-Bakhtiari; Bradly G Wouters; Giuseppe V Masucci; Emilia K Andersson; Eva Zavadova; Michal Vocka; Jan Spacek; Lubos Petruzelka; Bohuslav Konopasek; Pavel Dundr; Helena Skalova; Kristyna Nemejcova; Gerardo Botti; Fabiana Tatangelo; Paolo Delrio; Gennaro Ciliberto; Michele Maio; Luigi Laghi; Fabio Grizzi; Tessa Fredriksen; Bénédicte Buttard; Mihaela Angelova; Angela Vasaturo; Pauline Maby; Sarah E Church; Helen K Angell; Lucie Lafontaine; Daniela Bruni; Carine El Sissy; Nacilla Haicheur; Amos Kirilovsky; Anne Berger; Christine Lagorce; Jeffrey P Meyers; Christopher Paustian; Zipei Feng; Carmen Ballesteros-Merino; Jeroen Dijkstra; Carlijn van de Water; Shannon van Lent-van Vliet; Nikki Knijn; Ana-Maria Mușină; Dragos-Viorel Scripcariu; Boryana Popivanova; Mingli Xu; Tomonobu Fujita; Shoichi Hazama; Nobuaki Suzuki; Hiroaki Nagano; Kiyotaka Okuno; Toshihiko Torigoe; Noriyuki Sato; Tomohisa Furuhata; Ichiro Takemasa; Kyogo Itoh; Prabhu S Patel; Hemangini H Vora; Birva Shah; Jayendrakumar B Patel; Kruti N Rajvik; Shashank J Pandya; Shilin N Shukla; Yili Wang; Guanjun Zhang; Yutaka Kawakami; Francesco M Marincola; Paolo A Ascierto; Daniel J Sargent; Bernard A Fox; Jérôme Galon
Journal:  Lancet       Date:  2018-05-10       Impact factor: 79.321

9.  CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival.

Authors:  Valentina Mirisola; Ambra Zuccarino; Beatrice E Bachmeier; Maria Pia Sormani; Judith Falter; Andreas Nerlich; Ulrich Pfeffer
Journal:  Eur J Cancer       Date:  2009-07-29       Impact factor: 9.162

10.  Clinical implication of CXCL12 expression in gastric cancer.

Authors:  Sumiya Ishigami; Shoji Natsugoe; Hiroshi Okumura; Masataka Matsumoto; Akihiro Nakajo; Yoshikazu Uenosono; Takaaki Arigami; Yasuto Uchikado; Tetsuro Setoyama; Hideo Arima; Shuichi Hokita; Takashi Aikou
Journal:  Ann Surg Oncol       Date:  2007-07-26       Impact factor: 5.344

View more
  6 in total

Review 1.  The Roles of Tissue-Resident Memory T Cells in Lung Diseases.

Authors:  Rui Yuan; Jiang Yu; Ziqiao Jiao; Jinfei Li; Fang Wu; Rongkai Yan; Xiaojie Huang; Chen Chen
Journal:  Front Immunol       Date:  2021-10-11       Impact factor: 7.561

Review 2.  Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.

Authors:  Aïssata Aimée Goïta; Dominique Guenot
Journal:  Cancers (Basel)       Date:  2022-04-02       Impact factor: 6.639

3.  High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy.

Authors:  Fabio Walther; Jana Ladina Berther; Jasmin Zeindler; Gad Singer; Alexandros Lalos; Michaela Ramser; Simone Eichelberger; Robert Mechera; Savas Soysal; Simone Muenst; Alberto Posabella; Uwe Güth; Sylvia Stadlmann; Luigi Terracciano; Raoul A Droeser
Journal:  BMC Cancer       Date:  2022-04-09       Impact factor: 4.430

Review 4.  The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis.

Authors:  Maria Wozniakova; Jozef Skarda; Milan Raska
Journal:  Pathol Oncol Res       Date:  2022-07-21       Impact factor: 2.874

5.  T-Cell Infiltration and Immune Checkpoint Expression Increase in Oral Cavity Premalignant and Malignant Disorders.

Authors:  Subin Surendran; Usama Aboelkheir; Andrew A Tu; William J Magner; S Lynn Sigurdson; Mihai Merzianu; Wesley L Hicks; Amritha Suresh; Keith L Kirkwood; Moni A Kuriakose
Journal:  Biomedicines       Date:  2022-07-30

Review 6.  Molecular Determinants and Other Factors to Guide Selection of Patients for Hepatic Resection of Metastatic Colorectal Cancer.

Authors:  Thomas M Diehl; Daniel E Abbott
Journal:  Curr Treat Options Oncol       Date:  2021-07-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.